STADA continues on the path of growth in 2023. The company has maintained double-digit sales and profit growth in the past financial year.
The pharmaceutical company saw its sales grow by 14% this year to €3.73 billion. This sales growth was led mainly by the Consumer Healthcare segment, which accounted for 40% of the group's total sales, and sales in this division increased by 17% year-on-year to almost 1.5 billion euros. This increase improves and strengthens the company's position in strategic markets such as Belgium, France, Italy and Spain.
In the segment of the Generic, their sales increased in 6% arriving to the 1.500 million euros and equivale to 40% of the total sales of the group. Nevertheless, the greater growth for the company the past 2023 was in Speciality and the sales increased in this area 25%, registering a figure of 749 million euros.
In how much to profits, the profits before taxes rose 19% with regard to the past year until the 802 million euros.
Peter Goldschmidt, the CEO of Stada, showed satisfied with the rsultados and indicates that "our performance follows progressing by in front of our main competitors. Our culture with business approach is generating new launchings of our wide wallet of products, in addition to a strong organic growth."